Ultragenyx settles DOJOLVI patent case, clearing generic entry from 2033
Ultragenyx settled its ANDA patent litigation with Navinta, allowing a generic DOJOLVI from January 1, 2033 under a non-exclusive, royalty-free license.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Ultragenyx has reached a settlement that lets Navinta market a generic version of DOJOLVI starting January 1, 2033, according to TradingView. The license is non-exclusive and royalty-free, and is subject to customary conditions and exceptions.
The agreement resolves Navinta's ANDA patent litigation over the drug. If pediatric exclusivity is granted for DOJOLVI, the license will run until July 1, 2033. Other patent suits over DOJOLVI against different ANDA filers remain pending in New Jersey court.
why it matters
For markets, the settlement means generic competition is unlikely before 2033, while the outcome of the remaining patent suits is still unresolved. Investors may watch the New Jersey court, since its rulings could affect how long the drug's revenue is protected.
tags
instruments
sources
- Ultragenyx to allow generic DOJOLVI launch from Jan 1, 2033 under settlement — TradingView, 19 October 2026 at 13:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗